Comparative Pharmacology
Head-to-head clinical analysis: CARBATROL versus EXTENDED PHENYTOIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBATROL versus EXTENDED PHENYTOIN SODIUM.
CARBATROL vs EXTENDED PHENYTOIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by blocking voltage-gated sodium channels, inhibiting repetitive firing of action potentials. Also enhances GABAergic activity.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, reducing repetitive firing of action potentials, and decreasing synaptic transmission.
Initial dose 200 mg orally twice daily, increase by 200 mg/day at weekly intervals; maintenance 800-1200 mg/day in 2 divided doses extended-release capsules.
Oral: 100 mg three times daily; intravenous: 10-20 mg/kg loading dose at a maximum rate of 50 mg/min, then 100 mg every 6-8 hours maintenance.
None Documented
None Documented
Terminal elimination half-life 25-65 hours initially, then 12-17 hours after autoinduction; clinical context: requires dose adjustment after 3-5 weeks.
22–32 hours (mean 24 hours) in adults, dose-dependent due to saturable metabolism; may exceed 60 hours at high concentrations.
Renal: 70% as metabolites (including carbamazepine-10,11-epoxide) and 2-3% as unchanged drug; biliary/fecal: 30%.
Primarily hepatic metabolism (CYP2C9/CYP2C19), with <5% excreted unchanged renally. Fecal excretion accounts for minor elimination.
Category C
Category D/X
Anticonvulsant
Anticonvulsant